Literature DB >> 10913016

Hypertrophic effect of selective beta(1)-adrenoceptor stimulation on ventricular cardiomyocytes from adult rat.

M Schäfer1, K Frischkopf, G Taimor, H M Piper, K D Schlüter.   

Abstract

We investigated whether selective beta(1)-adrenoceptor stimulation causes hypertrophic growth on isolated ventricular cardiomyocytes from adult rat. As parameters for the induction of hypertrophic growth, the increases of [(14)C]phenylalanine incorporation, protein and RNA mass, and cell size were determined. Isoproterenol (Iso, 10 microM) alone had no growth effect. In the presence of the beta(2)-adrenoceptor antagonist ICI-118551 (ICI, 10 microM), Iso caused an increase in [(14)C]phenylalanine incorporation, protein and RNA mass, cell volume, and cross-sectional area. We showed for phenylalanine incorporation that the growth effect of Iso+ICI could be antagonized by beta(1)-adrenoceptor blockade with atenolol (10 microM) or metoprolol (10 microM), indicating that it was caused by selective beta(1)-adrenoceptor stimulation. The growth response to Iso+ICI was accompanied by an increase in ornithine decarboxylase (ODC) activity and expression. Inhibition of ODC by the ODC antagonist difluoromethylornithine (1 mM) attenuated this hypertrophic response, indicating that ODC induction is causally involved. The growth response to Iso+ICI was found to be cAMP independent but was sensitive to genistein (100 microM) or rapamycin (0.1 microM). The reaction was enhanced in the presence of pertussis toxin (10 microM). We conclude that selective beta(1)-adrenoceptor stimulation causes hypertrophic growth of ventricular cardiomyocytes by a mechanism that is independent of cAMP but dependent on a tyrosine kinase and ODC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10913016     DOI: 10.1152/ajpcell.2000.279.2.C495

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  15 in total

1.  A Cardiac Cell Outgrowth Assay for Evaluating Drug Compounds Using a Cardiac Spheroid-on-a-Chip Device.

Authors:  Jonas Christoffersson; Florian Meier; Henning Kempf; Kristin Schwanke; Michelle Coffee; Mario Beilmann; Robert Zweigerdt; Carl-Fredrik Mandenius
Journal:  Bioengineering (Basel)       Date:  2018-05-04

2.  Role of AKAP79/150 protein in β1-adrenergic receptor trafficking and signaling in mammalian cells.

Authors:  Xin Li; Mohammed M Nooh; Suleiman W Bahouth
Journal:  J Biol Chem       Date:  2013-10-11       Impact factor: 5.157

Review 3.  Modulation of beta-adrenergic receptor signaling in heart failure and longevity: targeting adenylyl cyclase type 5.

Authors:  David Ho; Lin Yan; Kousaku Iwatsubo; Dorothy E Vatner; Stephen F Vatner
Journal:  Heart Fail Rev       Date:  2010-09       Impact factor: 4.214

4.  PKA phosphorylates histone deacetylase 5 and prevents its nuclear export, leading to the inhibition of gene transcription and cardiomyocyte hypertrophy.

Authors:  Chang Hoon Ha; Ji Young Kim; Jinjing Zhao; Weiye Wang; Bong Sook Jhun; Chelsea Wong; Zheng Gen Jin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-17       Impact factor: 11.205

5.  Inhibition of p38 alpha MAPK rescues cardiomyopathy induced by overexpressed beta 2-adrenergic receptor, but not beta 1-adrenergic receptor.

Authors:  Pallavi S Peter; Jennifer E Brady; Lin Yan; Wei Chen; Stefan Engelhardt; Yibin Wang; Junichi Sadoshima; Stephen F Vatner; Dorothy E Vatner
Journal:  J Clin Invest       Date:  2007-04-19       Impact factor: 14.808

6.  Investigating β-adrenergic-induced cardiac hypertrophy through computational approach: classical and non-classical pathways.

Authors:  Ali Khalilimeybodi; Alireza Daneshmehr; Babak Sharif-Kashani
Journal:  J Physiol Sci       Date:  2017-07-03       Impact factor: 2.781

Review 7.  Cardiac hypertrophy induced by sustained beta-adrenoreceptor activation: pathophysiological aspects.

Authors:  Oleg E Osadchii
Journal:  Heart Fail Rev       Date:  2007-03-27       Impact factor: 4.654

8.  Adaptations to iron deficiency: cardiac functional responsiveness to norepinephrine, arterial remodeling, and the effect of beta-blockade on cardiac hypertrophy.

Authors:  Lexa Rae Turner; Daniel Aaron Premo; Brett Jason Gibbs; Megan Lesley Hearthway; Madelyne Motsko; Andrea Sappington; LeeAnn Walker; Michael Eugene Mullendore; Herbert George Chew
Journal:  BMC Physiol       Date:  2002-01-09

9.  Caveolin-3 regulates compartmentation of cardiomyocyte beta2-adrenergic receptor-mediated cAMP signaling.

Authors:  Peter T Wright; Viacheslav O Nikolaev; Thomas O'Hara; Ivan Diakonov; Anamika Bhargava; Sergiy Tokar; Sophie Schobesberger; Andrew I Shevchuk; Markus B Sikkel; Ross Wilkinson; Natalia A Trayanova; Alexander R Lyon; Sian E Harding; Julia Gorelik
Journal:  J Mol Cell Cardiol       Date:  2013-12-15       Impact factor: 5.000

Review 10.  Targeting cardiac β-adrenergic signaling via GRK2 inhibition for heart failure therapy.

Authors:  Alessandro Cannavo; Daniela Liccardo; Walter J Koch
Journal:  Front Physiol       Date:  2013-09-26       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.